BioSig Technologies Inc. (NASDAQ: BSGM) stock declined by 2.53% at the last close whereas the BSGM stock price soars by 5.52% in the pre-market trading session. BioSig Technologies is a medical technology business that sells a biomedical signal processing platform that enhances the signal quality and reveals the entire spectrum of ECG and intra-cardiac signals.
>> 7 Top Picks for the Post-Pandemic Economy <<
BSGM stock’ Recent Development
The Mark E. Josephson Twenty-Eight Annual State-of-the-Art Arrhythmia Symposium, which will take place electronically on September 11, 2021, has invited BioSig Technologies to attend.
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
Kenneth L. Londoner, Chairman, and CEO of BSGM stock stated,
The intellectual integrity of Dr. Josephson, as well as his steadfast commitment to the advancement of cardiac electrophysiology, was the motivating factor behind my choice to focus on basic research throughout the development of their flagship device, the PURE EP. Many of them who had the pleasure of knowing Dr. Josephson will recall his remarks that the industry needed to “move away from observation and toward invention.” These phrases sum up their company’s aim to provide more creative treatments for every arrhythmia sufferer. They are pleased to be invited to the conference that builds on his scientific and clinical legacy, four years after his death.
Moreover,
The PURE EP is a non-invasive class II device designed to improve electrophysiological procedure efficiency and efficacy. Over 60 clinicians have used the PURE EP System to finish over 1200 patient cases across eleven clinical sites. The FDA has granted the PURE EP System 510(k) approval.
Cardiac arrhythmia affects one in every 18 Americans. The most prevalent arrhythmia is atrial fibrillation, which affects over 33 million individuals globally, including over 6 million in the United States. By 2050, the number of persons with atrial fibrillation is anticipated to rise to 8-12 million. As per the Centers for Disease Control and Prevention, atrial fibrillation leads to more than 750,000 hospitalizations in the United States each year, costing $6 billion in healthcare costs.